Why Is 3D Systems (DDD) Down 7.9% Since Last Earnings Report?

3D Systems (DDD) shares have declined 7.9% since its last earnings report, underperforming the S&P 500, despite reporting a narrower-than-expected non-GAAP Q2 loss of 7 cents per share. However, revenues decreased 16.3% year-over-year to $94.8 million, missing consensus estimates, primarily due to a challenging macroeconomic environment and reduced OEM capital expenditures across both its Healthcare and Industrial segments. Despite these revenue headwinds, Zacks maintains a #2 (Buy) rating on DDD, projecting above-average returns in the coming months.

Analysis

Despite a recent 7.9% share price decline, 3D Systems (DDD) demonstrated improved bottom-line control in its second-quarter results, reporting a non-GAAP loss of 7 cents per share, which was narrower than both consensus estimates and the prior-year period. This operational improvement, however, was overshadowed by significant top-line pressure, as revenues fell 16.3% year-over-year to $94.8 million, missing forecasts. The revenue decline was attributed to a challenging macroeconomic environment and tariff uncertainties, leading to reduced capital expenditures from large OEM customers. This weakness was broad, with the Industrial Solutions segment declining 22.6% and Healthcare Solutions falling 7.9%. Within Healthcare, a bright spot emerged as the MedTech business grew 13% year-over-year, though this was offset by a sharp decline in the Dental segment against a tough prior-year comparison. The company's non-GAAP gross margin also contracted by 170 basis points to 39.2%. While analysts have remained quiet, the stock holds a Zacks Rank #2 (Buy), indicating an expectation of above-average returns despite the clear revenue headwinds and a poor 'D' score for value.

Key Decisions for Investors

• Investors should weigh the significant 16.3% year-over-year revenue decline and gross margin compression against the company's improved bottom-line performance, evidenced by a narrower-than-expected loss and a substantially reduced adjusted EBITDA loss.
• Given the stock's recent underperformance, the Zacks #2 (Buy) rating suggests potential for a near-term rebound, but this should be considered alongside the poor 'D' value score and broad demand weakness in the Industrial segment.
• Closely monitor the MedTech business, which grew 13% YoY, as a key internal growth driver, and track macroeconomic data on OEM capital expenditures, which the company identifies as the primary external headwind.